Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

By M. Maurer, K. Rosen, H. Hsieh, S. Saini, C. Grattan, A. Giménez-Arnau, S. Agarwal, R. Doyle, J. Canvin, A. Kaplan and 1 more. New England Journal of Medicine, 2013

966 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/f64643c05155fb56a654c20277dc94328fc91bab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Bernstein

Citations in the corpus

• The diagnosis and management of acute and chronic urticaria: 2014 update. (2014, background): “001) in those subjects receiving 150 and 300 mg every 4 weeks compared with placebo after 12 weeks.(568) The frequency of serious adverse events was slightly higher in subjects randomized to 300 mg (6%) compared with 150 mg (1%), 75 mg, (1%) or placebo (3%).”
• The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria (2018, background): “Omalizumab (anti-IgE) has been shown to be very effective and safe in the treatment of CSU (114-119).”